Given the role of L1CAM as a potential target for anti-cancer therapy and our preliminary data [5,6], we were prompted to investigate the in vivo effects of intraperitoneal anti-L1 mAb therapy using two distinct endometriosis mouse models. The gene discussed is L1CAM; the disease is endometriosis.